VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
AssigneeTrustees of Tufts College
InventorCharles B. Shoemaker
Life of this patent
Estimating the term…
Abstract
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent, methods, compositions and kits having a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a Botulinum toxin or an Anthrax toxin.
Claims11
A recombinant binding protein that specifically binds to a botulinum toxin B, wherein the binding protein comprises the amino acid sequence selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25, SEQ ID NO:
- 27, SEQ ID NO:
- 29, SEQ ID NO:
- 31, SEQ ID NO:
- 33, SEQ ID NO:
- 35, SEQ ID NO:
- 37, SEQ ID NO:
- 39, SEQ ID NO:
- 41, SEQ ID NO:
- 43, SEQ ID NO:
- 45, SEQ ID NO:
- 47, SEQ ID NO:
- 107, SEQ ID NO:
- 109, SEQ ID NO:
- 111, SEQ ID NO:
- 113, SEQ ID NO:
- 115, SEQ ID NO:
- 117, SEQ ID NO:
- 119, SEQ ID NO:
- 121, SEQ ID NO:
- 123, SEQ ID NO:
- 125, and a combination thereof.
A pharmaceutical composition for treating botulinum toxin B infection or for ameliorating a symptom of botulism due to botulinum toxin B in a mammalian subject in need thereof, the composition comprising a botulinum toxin B-neutralizing recombinant heterodimeric VHH comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 131, SEQ ID NO:
- 133, SEQ ID NO:
- 135 and SEQ ID NO:
- 137 and a pharmaceutically acceptable carrier or diluent.
A method of treating botulinum toxin B infection or ameliorating a symptom of botulism due to botulinum toxin B in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a botulinum toxin B-neutralizing recombinant heterodimeric VHH comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
- 131, SEQ ID NO:
- 133, SEQ ID NO:
- 135 and SEQ ID NO:
- 137 and a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.